Interaction of BAG-1 with Retinoic Acid Receptor and Its Inhibition of Retinoic Acid-induced Apoptosis in Cancer Cells*

Ru Liu, Shinichi Takayama, Yun Zheng, Barbara Froesch, Guo-quan Chen, Xin Zhang, John C. Reed, and Xiao-kun ZhangDagger

From The Burnham Institute, Cancer Research Center, La Jolla, California 92037

    ABSTRACT
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

BAG-1 (also known as RAP46) is an anti-apoptotic protein, which has been shown previously to interact with a number of nuclear hormone receptors, including receptors for glucocorticoid, estrogen, and thyroid hormone. We show here that BAG-1 also interacts with retinoic acid receptor (RAR). Gel retardation assays demonstrated that in vitro translated BAG-1 protein could effectively inhibit the binding of RAR but not retinoid X receptor (RXR) to a number of retinoic acid (RA) response elements (RAREs). A glutathione S-transferase-BAG-1 fusion protein also specifically bound RAR but not RXR. Interaction of BAG-1 and RAR could also be demonstrated by yeast two-hybrid assays. In transient transfection assays, co-transfection of BAG-1 expression plasmid inhibited the transactivation activity of RAR/RXR heterodimers but not RXR/RXR homodimers. When stably expressed in breast cancer cell lines, BAG-1 inhibited binding of RAR/RXR heterodimer to a number of RAREs and suppressed RA-induced growth inhibition and apoptosis. In addition, RA-induced suppression of Bcl-2 expression was abrogated by overexpression of BAG-1. These results demonstrate that BAG-1 can regulate retinoid activities through its interaction with RAR and suggest that elevated levels of BAG-1 protein could potentially contribute to retinoid resistance in cancer cells.

    INTRODUCTION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Development of a multicellular organism requires tightly regulated cellular processes, such as proliferation, differentiation, and cell death. Failure to maintain the balance among these fundamental and mechanistically related processes may result in abnormal cell growth, as seen in cancer cells where cell death is often inhibited (1, 2). Retinoids, a group of natural and synthetic vitamin A derivatives, are currently used to treat epithelial cancer and promyelocytic leukemia and are being evaluated for prevention and therapy of other human cancers (3, 4). The anti-cancer effects of retinoids are mainly due to their inhibition of cell proliferation, induction of cell differentiation, and promotion of apoptosis. Retinoids alone or in combination with other stimuli induce apoptosis during normal development and in different types of cancer cells in vitro (5-11). However, it remains largely unknown how retinoid-induced apoptosis is regulated.

The effects of retinoids are mainly mediated by two classes of nuclear receptors, the retinoic acid receptors (RARs)1 and retinoid X receptors (RXRs). RARs and RXRs are encoded by three distinct genes (alpha , beta , and gamma ) and are members of the steroid/thyroid/retinoid hormone receptor superfamily that function as ligand-activated transcription factors (12-14). 9-cis RA is a high affinity ligand for both RARs and RXRs, whereas all-trans-RA (trans-RA) is a ligand for only RARs. RARs and RXRs primarily function as RXR/RAR heterodimers that bind to a variety of RA response elements (RAREs) and regulate their transactivation activities.

Regulation of gene expression either positively or negatively by nuclear hormone receptors is modulated by additional factors. Some of them appear to provide a direct link to the core transcriptional machinery and to modulate chromatin structure (15), such as SRC-1 (16), SUG-1 (17), TIF-1 (18), RIP-140 (19), N-CoR (25), SMRT (26), TIF-2 (20), GRIP-1 (21), p160 (22), CBP (23), AIB1 (8), and ACTR (24), whereas a number of other cellular proteins, such as AP-1, have been implicated in the regulation of nuclear hormone receptor activity, probably through their interaction with receptors (27).

The involvement of retinoid receptors in retinoid-induced apoptosis has been demonstrated in several studies. Expression of RARbeta may be involved in the apoptosis of mesenchyme of the interdigital regions during mouse limb development (28). RARbeta is required for RA-induced apoptosis of breast cancer (5) and lung cancer (7) cells, whereas activation of RXR is essential for RA-induced HL-60 cell apoptosis (29). In 4-HPR-induced apoptosis, activation of RARgamma may be involved (30, 31), whereas regulation of activation-induced apoptosis of T-cells by 9-cis RA requires activation of both RARs and RXRs (32).

Although much interest has been directed to the role of retinoid-induced apoptosis in both physiological and pathological processes, very little is known regarding regulation of the process. It is believed that apoptosis, once triggered, proceeds through a central death pathway in which specific cellular proteases and endonucleases are activated (1, 2, 33). Members of the Bcl-2 family play an important role in the regulation of the central death pathway. Bcl-2 can suppress induction of apoptosis in many systems, whereas Bax promotes apoptosis. In addition, several other proteins that modulate Bcl-2 activity by interacting with Bcl-2 have been described (1, 2, 33). One of these genes, BAG-1 (for Bcl-2-associated anti-death <A><AC>g</AC><AC>&cjs1142;</AC></A>ene 1), was cloned from a murine embryo cDNA library using a protein-protein interaction technique (34). Two differently localized BAG-1 isoforms, the long BAG-1 isoform and the short BAG-1 isoform, generated by alternative translation initiation are expressed in mammalian cells (35). Whether two isoforms act differently remains to be determined. Recent studies demonstrated that co-expression of BAG-1 and Bcl-2 in Jurkat lymphoid cells, NIH 3T3 fibroblasts, and melanoma cells promoted the survival of these cells in response to a variety of apoptotic stimuli (34, 36, 37). In addition to Bcl-2, BAG-1 also interacts with Raf-1 (38), resulting in activation of its kinase activity. Furthermore, BAG-1 can interact with hepatocyte growth factor receptor and platelet-derived growth factor receptor and enhance the ability of these receptors to transduce signals for cell survival (39). These observations suggest that BAG-1 may function as an adaptor to mediate the interaction between survival factors and apoptotic machinery and may also play a role in regulating cellular proliferation. The recent observation that BAG-1 binds tightly to Hsp70/Hsc70-family proteins and modulates their chaperone activity (40-42) suggests that the ability of BAG-1 to alter the activities of diverse groups of proteins involved in cell growth control may be attributed to its effects on Hsp70/Hsc70 proteins.

Interestingly, the human BAG-1 homolog (also known as RAP46) was cloned from a human liver cDNA library by virtue of its interaction with the glucocorticoid receptor (43). In vitro, RAP46 interacts with a number of nuclear hormone receptors, including estrogen receptor and thyroid hormone receptor (TR) (43). Since molecular chaperones are known to play an important role in controlling the activity of many members of the steroid/thyroid/retinoid receptor family (44), it is possible that BAG-1 could alter the function of these transcriptional regulators. Before this report, however, it was unknown whether BAG-1 regulates the activities of the nuclear hormone receptors and whether BAG-1 interacts with retinoid receptors.

Here we demonstrate that short BAG-1 isoform interacts with the RAR but not the RXR both in vitro and in vivo. GST pull-down and the yeast two-hybrid assays show that BAG-1 directly interacts with RAR but not RXR. Moreover, BAG-1 inhibits RAR/RXR heterodimer DNA binding and suppresses RA-induced transactivation activity of RARs on various RAREs. Overexpression of BAG-1 in MCF-7 and ZR-75-1 breast cancer cells reduces the ability of trans-RA to inhibit the growth and induce apoptosis, as well as its modulation of Bcl-2 expression. Taken together, our results demonstrate that BAG-1 can physically interact with RARs and is an important component in the retinoid response pathway. Our findings suggest that this protein-protein interaction may play a role in the regulation of retinoid-induced growth inhibition and apoptotic processes, potentially contributing to retinoid resistance in cancer.

    MATERIALS AND METHODS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Cell Culture-- Monkey kidney CV-1 cells and breast cancer MCF-7 cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, and ZR-75-1 breast cancer cells were maintained in RPMI 1640 medium supplemented with 10% fetal calf serum.

Growth Inhibition Assay-- Cells were seeded at 1,000-2,000 cells/well in 96-well plates and treated 24 h later with various concentrations of trans-RA for 7 days. Media and trans-RA were changed every 48 h. Relative viable cell number was determined using the MTT assay (52).

Apoptosis Analysis-- For the terminal deoxynucleotidyl transferase assay (5), cells were treated with or without 10-6 M trans-RA. After 48 h, cells were trypsinized, washed with phosphate-buffered saline, fixed in 1% formaldehyde in phosphate-buffered saline, washed with phosphate-buffered saline, resuspended in 70% ice-cold ethanol, and stored at -20 °C overnight. Cells were then labeled with biotin-16-dUTP by terminal transferase and stained with avidin-fluorescein isothiocyanate (Boehringer Mannheim). Fluorescently labeled cells were analyzed using a FACScater-Plus. Representative histograms are shown.

Antibodies and Immunoblotting-- Cells were lysed in 150 mM NaCl, 10 mM Tris, pH7.4, 5 mM EDTA, 1% Triton X-100 and protease inhibitors phenylmethylsulfonyl fluoride, aprotinin, leupeptins, and pepstatin. Equal amounts of lysates (50 µg) were boiled in SDS sample buffer, resolved by SDS-polyacrylamide gel electrophoresis, and transferred onto nitrocellulose membrane. After transfer, the membranes were blocked in TBST (50 mM Tris, pH7.5, 150 mM NaCl, 0.1% Tween 20) containing rabbit anti-Bcl-2 serum. The membranes were then washed three times with TBST and then incubated for 1 h at room temperature in TBST containing horseradish peroxidase-linked anti-rabbit immunoglobulin. After three washes in TBST, immunoreactive products were detected by chemiluminescence with an enhanced chemiluminescence system (ECL, Amersham Pharmacia Biotech).

Transient and Stable Transfection Assay-- For CV-1 cells, 1 × 105 cells were plated per well in a 24-well plates 16-24 h before transfection as described previously (45). For ZR-75-1 cells, 5 × 105 cells/well were seeded in 6-well culture plates. A modified calcium phosphate precipitation procedure was used for transient transfection (45). For CV-1 cells, 100 ng of reporter plasmid, 150 ng of beta -galactosidase expression vector (pCH 110, Amersham), and various amounts of BAG-1 expression vector that expresses short BAG-1 isoform (35) were mixed with carrier DNA (pBluescript) to 1,000 ng of total DNA/well. Reporter plasmids beta RARE-tk-CAT, TREpal-tk-CAT, and TREMHC-tk-CAT have been previously described (45-48). For stable transfection, the pRc/CMV-BAG-1 plasmid (34) that expresses short BAG-1 isoform was stably transfected into MCF-7 or ZR-75-1 cells using calcium phosphate precipitation method, followed by selection using G418 (Life Technologies, Inc.) as described (5).

Preparation of Receptor, BAG-1, and Nuclear Protein-- cDNAs for RARalpha , RXRalpha , estrogen receptor, and BAG-1, which expresses short BAG-1 isoform cloned into pBluescript (Stratagene), were transcribed by using T7 or T3 RNA polymerase, and the transcripts were translated in the rabbit reticulocyte lysate system (Promega) as described previously (45). The relative amounts of the translated proteins were determined by separating the [35S]methionine-labeled proteins on SDS-polyacrylamide gels, quantitating the amount of incorporated radioactivity and normalizing it relative to the content of methionine residues in each protein. To synthesize receptor fusion protein, RARgamma or RXRalpha cDNAs were cloned in-frame into the bacterial expression vector pGex.2T (Amersham) as described (45). Preparation and purification of GST-BAG-1 and GST-BAG-1(Delta 172-218) fusion proteins has been described (41). Preparation of nuclear extract was described previously (6).

Gel Retardation Assay-- Analysis of in vitro synthesized or bacterially expressed receptor proteins or nuclear proteins by gel retardation was described previously (45). To analyze the effect of BAG-1 protein, in vitro synthesized BAG-1 protein was preincubated with receptor protein at room temperature for 10 min before the gel retardation assay. The oligonucleotides used for gel retardation assays were beta RARE (TGTAGGGTTCACCGAAAGTTCAGTC) (46); TREpal (TGAGGTCATGACCTGA) (45); DR-5-RARE(TGTAGGGTTCACACTGAGTTCACTCA); and DR-2-RARE(AGGTCAAAAGGTCAG).

GST Pull-down Assay-- To analyze the interaction between BAG-1 and RAR, GST-BAG-1 fusion protein was immobilized on glutathione-Sepharose beads as described (52). As a control, GST prepared under the same conditions was also immobilized. The beads were preincubated with bovine serum albumin (1 mg/ml) at room temperature for 5 min. 35S-Labeled in vitro synthesized receptor proteins (2 to 5 µl, depending on translation efficiency) Bcl-2 or Hsc70 were then added to the beads. The beads were then continuously rocked for 1 h at 4 °C in a final volume of 200 µl in EBC buffer (140 mM NaCl, 0.5% Nonidet P-40, 100 mM NaF, 200 µM sodium orthovanadate, and 50 mM Tris, pH 8.0). After washing five times with NETN buffer (100 mM NaCl, 1 mM EDTA, 20 mM Tris, pH 8.0, 0.5% Nonidet P-40), the bound proteins were analyzed by SDS-polyacrylamide gel electrophoresis.

Two-hybrid Assay-- For the yeast two-hybrid assay, the yeast two-hybrid system from CLONTECH Inc. (Palo Alto, CA) was used (52). BAG-1 cDNA was cloned into the yeast expression vector pGAD424 to generate an in-frame fusion with the Gal4 activation domain. RARgamma or RXRalpha cDNAs were cloned into pGBT11 or pGBT9, respectively, to produce an in-frame fusion with Gal4 DNA binding domain. RARgamma was also cloned into pGAD426 that contains Gal4 activation domain to study the interaction between RARgamma and RXRalpha . The yeast reporter strain Y190 containing a LacZ reporter plasmid with Gal4 binding sites was used for transformation. beta -Galactosidase activity was determined following the conditions provided by the manufacturer.

    RESULTS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Inhibition of Retinoid Receptor DNA Binding by BAG-1-- We investigated whether BAG-1 could interact with retinoid receptors by studying the effect of BAG-1 protein on binding of retinoid receptors to their target DNA sequences. In vitro synthesized RAR and RXR formed a strong RAR/RXR heterodimer complex with the TREpal as described previously (45). When increasing amounts of in vitro synthesized short BAG-1 isoform protein were incubated with RAR and RXR, the binding of RAR/RXR heterodimers was inhibited in a BAG-1 concentration-dependent manner (Fig. 1a). At a 5 M excess of BAG-1 protein relative to RAR/RXR, the binding was almost completely inhibited. The effect of BAG-1 on RAR/RXR binding was specific because similar amounts of estrogen receptor did not show any effect. BAG-1 also effectively inhibited the binding of TR/RXR to the TREpal probe (Fig. 1b), consistent with a prior report that BAG-1 can interact with TR (43). To study whether the inhibitory effect of BAG-1 on RAR/RXR heterodimer binding is specific to the TREpal, we used another RA responsive element (beta RARE), which is derived from the RARbeta promoter (46). As shown in Fig. 1c, binding of RAR/RXR on the beta RARE was also inhibited by the addition of BAG-1 protein. Similar results were obtained with other RAREs, including CRBPI-RARE and ApoAI-RARE (data not shown). Thus, inhibition of RAR/RXR binding to their target DNA sequences by BAG-1 is independent of RAREs.


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 1.   Inhibition of RAR DNA binding by BAG-1. a, inhibition of RAR/RXR heterodimer binding by BAG-1. In vitro synthesized RARalpha and RXRalpha were preincubated with the indicated molar excess of in vitro synthesized BAG-1 or estrogen receptor (ER). Unprogrammed reticulocyte lysate was used to maintain an equal protein concentration in each reaction. After this preincubation, the reaction mixtures were incubated with 32P-labeled TREpal and analyzed by the gel retardation assay. The open arrow indicates nonspecific binding. b, inhibition of TRalpha /RXRalpha binding by BAG-1. In vitro synthesized TRalpha and RXRalpha were preincubated with the indicated molar excess amount of in vitro synthesized BAG-1 and analyzed by the gel retardation assay using the TREpal as a probe. c, inhibition of RARalpha /RXRalpha binding on the beta RARE by BAG-1. In vitro synthesized RARalpha and RXRalpha were preincubated with the indicated molar excess amount of in vitro synthesized BAG-1 and analyzed by the gel retardation assay using the beta  RARE as a probe. d, inhibition of DNA binding of bacterially expressed RAR but not RXR by BAG-1. Bacterially expressed RARgamma or RXRalpha protein was preincubated with 6 µl of in vitro synthesized BAG-1 and analyzed by the gel retardation assay using the TREpal as a probe.

We next determined whether inhibition of RAR/RXR heterodimer binding by BAG-1 is due to interaction of BAG-1 with RAR or RXR. Since in vitro synthesized RAR or RXR alone does not bind efficiently to RARE, we used bacterially expressed RAR or RXR protein. When a 5-fold molar excess of BAG-1 protein was added, the binding of RARgamma was significantly inhibited, whereas binding of RXRalpha was not affected (Fig. 1d). These results suggest that inhibition of RAR/RXR or TR/RXR heterodimer DNA binding by BAG-1 is likely due to its interaction with RAR or TR but not with RXR.

Interaction of BAG-1 with Retinoid Receptors-- To further study the interaction between BAG-1 and RAR, we used an in vitro GST pull-down assay. A GST-BAG-1 fusion protein was expressed in bacteria and immobilized on glutathione-Sepharose beads. The beads were then incubated with in vitro synthesized 35S-labeled RAR or RXR protein. After extensive washing, the mixtures were analyzed on a SDS-polyacrylamide gel. In comparison to the input lane, significant amounts of labeled RAR but not RXR were retained by GST-BAG-1-Sepharose beads but not by GST control beads (Fig. 2). For control, Bcl-2, a known BAG-1 interacting protein (34), bound strongly to GST-BAG-1 beads. We also employed a BAG-1 mutant protein in which the last 47 amino acid residues are deleted from its C-terminal end (41). This mutant protein (BAG-1/Delta c) can interact with Bcl-2 but not with Hsc70. Interestingly, labeled RAR but not RXR was also retained by the mutant BAG-1, thus implying that the interaction of BAG-1 with RAR is independent of its binding to Hsc70.


View larger version (38K):
[in this window]
[in a new window]
 
Fig. 2.   Analysis of RAR-BAG-1 interaction by the GST pull-down assay. BAG-1 or a BAG-1 C-terminal deletion mutant (BAG-1/Delta c) was expressed in bacteria using the pGex.4T expression vector. The GST-BAG-1 proteins were immobilized on glutathione-Sepharose beads. As a control, the same amount of GST was also immobilized. 35S-Labeled RARalpha , RXRalpha , or Bcl-2 was then mixed with the beads. After extensive washing, the bound proteins were analyzed by SDS-polyacrylamide gel electrophoresis. The input proteins are shown for comparison (left panel). For comparison, binding of GST-BAG-1 and GST-BAG-1/Delta c to Hsc70 was shown in right panel.

Interaction between RAR and BAG-1 was also evaluated by the two-hybrid assay in yeast. Fig. 3 shows that co-transformation of BAG-1 and RARgamma significantly activated the reporter in beta -gal filter assay, whereas co-transformation of BAG-1 and RXRalpha did not. Interaction between BAG-1 and RARgamma was specific because co-transformation of either BAG-1 or RARgamma with the corresponding empty vector did not activate the reporter gene. Thus, RAR and BAG-1 also interact in intact cells.


View larger version (47K):
[in this window]
[in a new window]
 
Fig. 3.   RAR and BAG-1 interact in yeast. The RARalpha and BAG-1 cDNAs were cloned into the yeast expression vectors pGAD and pGBT, respectively. The resulting expression vectors were introduced into Y190 yeast cells. The yeast transformants were streaked on a filter and assayed for beta -galactosidase activity. 11+424/Bag-1, pGBT and pGAD/BAG-1; 11/Agamma +424, pGBT/RARgamma  + pGAD; 11/Agamma +424/Bag-1; pGBT RARgamma  + pGAD/BAG-1; 9/Xalpha +426, pGBT/RXRalpha  + pGAD; 9/Xalpha +426/Agamma , pGBT/RXRalpha  + pGAD/RARgamma ; 9/Xalpha +424/Bag-1, pGBT/RXRalpha  + pGAD/BAG-1; 9+426/Agamma ; pGBT + pGAD/RARgamma ; 9+424, pGBT + pGAD.

Inhibition of Transactivation Activity of Retinoid Receptors by BAG-1-- To further examine the BAG-1-RAR interaction, we studied the effects of the short BAG-1 isoform on RAR transactivation activity on a number of RAREs by transient transfection assay. When CV-1 cells were transiently transfected with RARalpha expression vector together with either TREpal-tk-CAT (Fig. 4a) or beta RARE-tk-CAT (Fig. 4b), trans-RA-induced reporter gene activity was markedly inhibited by co-transfection of BAG-1 expression plasmid in a concentration-dependent manner. The effect is specific to BAG-1 because co-transfection of similar amounts of empty expression vector (pcDNA3) did not inhibit trans-RA-induced gene expression. BAG-1 also showed inhibitory effect on trans-RA-induced RARbeta activity on the TREpal. However, the trans-RA-independent RARbeta activity was not affected. This suggests that ligand-dependent RAR activity is more sensitive to the inhibitory effect of BAG-1. A similar inhibitory effect of BAG-1 was also obtained when RARgamma expression vector was used (data not shown). We also studied the effects of BAG-1 on thyroid hormone (T3)-induced TRalpha activity, and we observed a significant inhibitory effect of BAG-1 on TRalpha (Fig. 4d), consistent with the ability of BAG-1 to bind the TR protein (Fig. 1b; Ref. 43). To determine the effect of BAG-1 on RXR homodimer activity, we co-transfected TREpal-tk-CAT reporter plasmid and RXRalpha expression vector. However, the 9-cis-RA-induced RXRalpha homodimer activity was not affected by co-transfection of BAG-1 (Fig. 4e), consistent with our observation that BAG-1 does not interact with RXRalpha in vitro (Figs. 1d, 2, and 3).


View larger version (41K):
[in this window]
[in a new window]
 
Fig. 4.   Inhibition of transactivation activities of nuclear receptors by BAG-1. a, inhibition of RARalpha activity on the TREpal by BAG-1. The TREpal-tk-CAT reporter plasmid was co-transfected into CV-1 cells with 100 ng of RARalpha expression vectors together with the indicated amounts of BAG-1 expression vector or the empty plasmid (pcDNA3) into CV-1 cells. Transfected cells were treated with  or without square  10-7 M trans-RA and assayed 24 h later for CAT activity. b, inhibition of RARalpha activity on the beta RARE by BAG-1. The beta RARE-tk-CAT was co-transfected with 100 ng of RARalpha expression vectors together with the indicated amounts of BAG-1 expression vector or the empty vector (pcDNA3) into CV-1 cells, Transfected cells were treated with  or without square  10-7 M trans-RA and assayed 24 h later for CAT activity. c, inhibition of RARbeta activity on the TREpal by BAG-1. The TREpal-tk-CAT reporter (47) was co-transfected by either 100 ng of RARbeta expression vector together with the indicated amounts of pcDNA3/BAG-1 or pcDNA3. Cells were treated with  or without square  10-7 M trans-RA. d, inhibition of TR/RXR activities by BAG-1 MHC-TRE-tk-CAT reporter plasmid was co-transfected with 100 ng of TRbeta expression vectors together with the indicated amounts of BAG-1 expression vector or the empty vector (pcDNA3) into CV-1 cells. Transfected cells were treated with or without 10-7 M T3 and assayed 24 h later for CAT activity. e, effect of BAG-1 on RXR homodimer activity on the TREpal. The TREpal-tk-CAT was cotransfected with 100 ng of RXRalpha expression vector together with the indicated amount of BAG-1 or empty vector. Cells were treated with  or without square  10-7 M 9-cis-RA.

Overexpression of BAG-1 Inhibits Trans-RA-induced Cancer Cell Apoptosis-- The above data suggest that BAG-1 may function as a modulator of trans-RA-induced biological responses. We previously showed that trans-RA effectively inhibits the growth and induces apoptosis of some human breast cancer cell lines (5). We, therefore, stably expressed BAG-1 in human breast cancer cell lines MCF-7 and ZR-75-1. MCF-7/BAG-1(#3), 75-1/BAG-1(#5), and 75-1/BAG-1(#6) that stably expressed high levels of the transfected BAG-1 plasmid (data not shown) were chosen to examine the effect of BAG-1 overexpression on RA activities. As shown in Fig. 5a, trans-RA effectively inhibited the growth of parental MCF-7 and ZR-75-1 cells. However, the BAG-1-overexpressing clones displayed resistance to the growth inhibitory effects of trans-RA. The growth of the MCF-7/BAG-1(#3) was even stimulated by trans-RA (Fig. 5a). Although trans-RA did not stimulate the growth of 75-1/BAG-1(#5) and 75-1/BAG-1(#6) cells, its inhibitory effect on the growth of these cells was significantly reduced as compared with its effect on ZR-75-1 cells (Fig. 5b). The effect on trans-RA activity observed above was specific because clones stably transfected with the empty vector, MCF-7/neo and 75-1/neo, exhibited similar responses to trans-RA as that observed with the parental cell lines. Thus, BAG-1 partially abrogates the growth inhibitory effects of trans-RA on human breast cancer cells.


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 5.   Overexpression of BAG-1 reduces trans-RA-induced growth inhibition of breast cancer cells. a, effect of constitutive BAG-1 expression on RA-induced growth inhibition in MCF-7 cells. The growth of BAG-1 stable transfectant, MCF-7/BAG-1(#3) (shaded triangle), parental MCF-7 cells (black box), and MCF-7 cells transfected with empty vector (MCF-7/neo, shaded circle) in the absence or presence of the indicated concentration of trans-RA was determined by the MTT assay. b, effect of constitutive BAG-1 expression on trans-RA-induced growth inhibition in ZR-75-1 cells. The growth of BAG-1 overexpressing transfectants 75-1/BAG-1(#5) (black-triangle) and 75-1/BAG-1(#6) (black-diamond ), parental ZR75-1 cells (black-square), and ZR75-1 cells transfected with the empty vector (75-1/neo) (bullet ) in the absence or presence of the indicated concentrations of trans-RA was determined by the MTT assay.

We next investigated the effects of BAG-1 on trans-RA-induced apoptosis of ZR-75-1 and MCF-7 cells using the terminal deoxynucleotidyl transferase assay. Extensive DNA fragmentation was induced by trans-RA in ZR-75-1 and ZR-75-1/neo cells. In the typical experiment shown in Fig. 6a, about 39 and 33% of the ZR-75-1 and ZR-75-1/neo cells underwent apoptosis in response to trans-RA, respectively. However, ZR-75-1/BAG-1(#5) and ZR-75-1/BAG-1(#6) cells experienced much less DNA fragmentation under the same conditions, with only about 7 and 8% apoptotic cells, respectively. Similarly, the apoptogenic effect of trans-RA on MCF-7 cells was significantly reduced by BAG-1 overexpression (Fig. 6b). Thus, overexpression of BAG-1 inhibits trans-RA-induced apoptosis in breast cancer cells.


View larger version (34K):
[in this window]
[in a new window]
 
Fig. 6.   Overexpression of BAG-1 inhibits trans-RA-induced apoptosis of ZR-75-1 cells. a, inhibition of trans-RA-induced apoptosis in ZR-75-1 cells. b, inhibition of trans-RA-induced apoptosis in MCF-7 cells. Cells were treated with 10-6 M trans-RA for 48 h, and DNA fragmentation was determined by the terminal deoxynucleotidyl transferase assay. Representative histograms show relative apoptotic cell numbers. FL, fluorescence.

Overexpression of BAG-1 Abrogates Down-regulation of Bcl-2 by Trans-RA-- Retinoids have been shown to down-regulate the expression of Bcl-2 in leukemia (11). We therefore studied whether BAG-1 affected RA-regulated expression of Bcl-2 in MCF-7 cells. Bcl-2 was highly expressed in MCF-7 cells, and its expression level was significantly reduced by trans-RA as determined by immunoblotting. In MCF-7/BAG-1(#3)-stable transfectant, however, treatment of trans-RA had little or no effect on Bcl-2 expression (Fig. 7). These data suggest that BAG-1 may inhibit trans-RA-induced apoptosis at least in part through its effects on trans-RA-regulated genes, such as Bcl-2.


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 7.   Overexpression of BAG-1 prevents inhibition of Bcl-2 expression by trans-RA in MCF-7 cells. Cell lysates prepared from MCF-7/neo (NEO) and MCF-7/BAG-1(#3) (BAG-1) cells treated with 10-6 M trans-RA for the indicated time were electrophoresed in a SDS-polyacrylamide gel. After transfer to nitrocellulose membrane, Bcl-2 was detected with rabbit anti-Bcl-2 serum by Western blotting.

To further study the effect of BAG-1 on RAR-mediated gene regulation, we prepared nuclear extract from MCF-7, MCF-7/neo, and MCF-7/BAG-1(#3) cells and analyzed their binding to various RAREs, including beta RARE, DR-5-type RARE, and DR-2-type RARE. As shown in Fig. 8a, extracts from MCF-7 and MCF-7/neo showed strong binding complex to these RAREs, whereas binding of the slow-migrating complex observed in MCF-7 and MCF-7/neo cells was strongly inhibited in MCF-7/BAG-1(#3) cells. To determine the nature of the slow-migrating complex, extract from MCF-7 cells was incubated with either anti-RAR (alpha -RAR) or anti-RXR (alpha -RXR) antibody or nonspecific preimmune serum prior to DNA binding reaction. Fig. 8b shows that either anti-RAR or anti-RXR antibody, but not nonspecific serum, completely inhibited the formation of the complex, suggesting that the complex contains RAR and RXR. These data further demonstrate that overexpression of BAG-1 inhibits RAR/RXR binding and suggest that the alteration of RAR transcriptional activity may contribute to the effect of BAG-1 on RA responses.


View larger version (105K):
[in this window]
[in a new window]
 
Fig. 8.   Overexpression of BAG-1 inhibits DNA binding of RAR/RXR heterodimer in MCF-7 cells. a, an equal amount (3 µg) of nuclear extracts prepared from MCF-7, MCF-7/neo, and MCF-7/BAG-1(#3) was analyzed by gel retardation assay using beta RARE, DR-5-type RARE (DR-5) or DR-2-type RARE (DR-2) as a probe. b, effects of anti-RXR (alpha RXR) and anti-RAR (alpha RAR) antibodies on the binding of the slow-migrating binding complex. Nuclear extract (3 µg) from MCF-7 cells was incubated with antibody (Ab) for 30 min at room temperature before performance of the gel retardation assay using the beta RARE as a probe. The arrow indicates the slow-migrating complex, which had a binding that was inhibited by either alpha RXR or alpha RAR but not by nonspecific preimmune serum (NI).

    DISCUSSION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Previously, it was reported that BAG-1 (RAP46) can interact with several steroid hormone receptors (43). However, the biological effects of the interaction are unknown. In this report, we show that the short BAG-1 isoform that is known to be predominantly expressed in cytoplasm (35) can antagonize RAR activity through its direct interaction with RAR. Using gel retardation assays, we observed that BAG-1 inhibits binding of RAR/RXR heterodimers to several RAREs (Fig. 1). In GST-pull down assay, we found that BAG-1 directly interacts with RAR in solution (Fig. 2). By using yeast two-hybrid assays (Fig. 3), we showed that the BAG-1-RAR interaction could occur in vivo. Moreover, a functional interaction was demonstrated by our observation that co-transfection of BAG-1 inhibits trans-RA-induced RAR transactivation activities on several RAREs (Fig. 4). Furthermore, RAR/RXR RARE binding was abrogated in MCF-7 cells that express transfected BAG-1 (Fig. 8). Thus, the interaction of BAG-1 with steroid hormone receptors can be extended to RAR. We also present evidence here that BAG-1 can similarly prevent TR DNA binding and transactivation activity. However, BAG-1 does not interact with all nuclear hormone receptors, as shown here by the failure of BAG-1 to bind to and modulate the activity of RXR (Figs. 1d, 2, 3, and 4e).

Activation or repression of gene transcription by nuclear hormone receptors requires their interaction with multiple cellular co-regulatory factors. These include receptor co-activators, which exert their effect on receptor transactivation activity by mediating transcription-initiation complex formation and affecting chromatin structure (15), and receptor co-repressors, which bind to receptors in the absence of ligand and actively repress target gene transcription by impairing the activity of the basal transcription machinery (25). BAG-1 appears to function differently from receptor co-activators or co-repressors. It does not induce ligand-dependent gene activation nor does it cause repression of target gene transcription in the absence of ligand (Fig. 4a). Instead, interaction of RAR and BAG-1 resulted in inhibition of RAR DNA binding (Fig. 1) and trans-RA-induced RAR transactivation activities (Fig. 4). Thus, it may function as a modulator of RAR activities through the mechanisms that resemble the effect of AP-1, which was previously shown to inhibit trans-RA-induced RAR activity by preventing RAR binding to target DNA sequences in promoters (27). However, whether BAG-1 affects recruitment of co-activator or co-repressor by RAR remains to be determined.

The mechanism by which BAG-1 inhibits RAR binding to DNA and transactivation activity remains to be elucidated. Recently, BAG-1 was reported to bind tightly with Hsp70/Hsc70-family proteins and modulate their activity (40-42). Although the role of molecular chaperones in transcriptional activation by retinoid receptors remains controversial (49, 50), Hsp70/Hsc70 and other heat shock proteins are known to participate in the regulation of several other steroid hormone receptors (44). It is therefore tempting to speculate that BAG-1 may also influence RAR activity through Hsp70/Hsc70-mediated conformational changes that prevent it from binding DNA and transactivating retinoid-responsive target genes. Interestingly, a deletion mutant of BAG-1 lacking its C-terminal 47 amino acids, which does not bind to Hsc70, was capable of binding to RAR in vitro (Fig. 2). Thus, the domains in BAG-1 required for interactions with RAR and Hsp70 appear to be separable. Unfortunately, when expressed in mammalian cells, the BAG-1 mutant protein was unstable, precluding functional evaluation of its effects on RAR-mediated gene expression. Thus, the relevance of BAG-1 interactions with Hsp70-family proteins to its function as inhibitor of RAR remains to be determined.

One of the interesting features of BAG-1 is its ability to promote cell survival (34, 36, 37). The effect was previously attributed to its interaction with Bcl-2 (34). In addition, BAG-1 interacts with platelet-derived growth factor and hepatocyte growth factor receptors, enhancing their ability to transduce signals that promote cell survival (39). BAG-1 can also bind to Raf-1 and activate its kinase activity (38). Our observations that overexpression of BAG-1 inhibits trans-RA-induced apoptosis (Fig. 6) and prevents trans-RA-induced down-regulation of Bcl-2 expression (Fig. 7) suggest that interaction with RAR may represent another mechanism by which BAG-1 promotes cell survival. These observations also suggest that overexpression of BAG-1 may contribute to retinoid resistance in certain malignancies. Taken together with recent observations that BAG-1 protein levels are elevated in breast and prostate cancers (51), BAG-1 may represent an important regulator of cell survival and growth, which may contribute in multiple ways to tumorigenesis and resistance to therapy.

    ACKNOWLEDGEMENT

We thank S. Waldrop for preparation of the manuscript.

    Note Added in Proof

The longer isoform of BAG-1, BAG-1L, has been reported recently to enhance androgen receptor transactivation, implying that BAG-1 family proteins may either potentiate or suppress the actions of specific nuclear receptors (Froesch, B. A., Takayama, S., and Reed, J. C. (1998) J. Biol. Chem. 273, 11660-11666).

    FOOTNOTES

* This work was supported in part by National Institutes of Health Grant CA60988 and CA67329, the United States Army Medical Research Program Grant DAMD17-4440, the California Breast Cancer Research Program Grant 3BP-0018, and the California Tobacco-related Disease Research Program Grant 6RT-0168.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: The Burnham Institute, Cancer Research Center, 10901 N. Torrey Pines Rd., La Jolla, CA 92037. Tel.: 619-646-3141; Fax: 619-646-3195; E-mail: xzhang{at}ljcrf.edu.

1 The abbreviations used are: RAR, retinoic acid receptor; RXR, retinoid X receptor; RARE, retinoic acid response elements; TR, thyroid hormone receptor; MTT, 3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium bromide; GST, glutathione S-transferase; tk, thymidine kinase; MHC, myosin heavy chain; CAT, chloramphenicol acetyl- transferase.

    REFERENCES
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

  1. White, E. (1996) Genes Dev. 10, 1-15[CrossRef][Medline] [Order article via Infotrieve]
  2. Reed, J. C. (1994) J. Cell. Biol. 124, 1-6[Medline] [Order article via Infotrieve]
  3. Gudas, L. J., Sporn, M. B., and Roberts, A. B. (1994) in The Retinoids (Sporn, M. B., Roberts, A. B., and Goodman, D. S., eds), pp. 443-520, Raven Press, New York
  4. Hong, W. K., and Itri, L. M. (1994) in The Retinoids (Sporn, M. B., Roberts, A. B., and Goodman, D. S., eds), pp. 597-630, Raven Press, Ltd., New York
  5. Liu, Y., Lee, M.-O., Wang, H.-G., Li, Y., Hashimoto, Y., Klaus, M., Reed, J. C., and Zhang, X.-k. (1996) Mol. Cell. Biol. 16, 1138-1149[Abstract]
  6. Wu, Q., Dawson, M. I., Zheng, Y., Hobbs, P. D., Agadir, A., Jong, L., Li, Y., Liu, R., Lin, B., and Zhang, X.-k. (1997) Mol. Cell. Biol. 17, 6598-6608[Abstract]
  7. Li, Y., Dawson, M. I., Agadir, A., Lee, M.-O., Jong, L., Hobbs, P. D., and Zhang, X.-k. (1998) Int. J. Cancer 75, 88-95[CrossRef][Medline] [Order article via Infotrieve]
  8. Anzick, S. L., Kononen, J., Walker, R. L., Azorsa, D. O., Tanner, M. M, Guan, X.-Y., Sauter, G., Kallioniemi, O.-P., Trent, J. M., and Meltzer, P. S. (1997) Science 277, 965-968[Abstract/Free Full Text]
  9. Chao, W. R., Hobbs, P. D., Jong, L., Zhang, X.-k., Zheng, Y., Wu, Q., Shroot, B., and Dawson, M. I. (1997) Cancer Lett. 115, 1-7[CrossRef][Medline] [Order article via Infotrieve]
  10. Ponzoni, M., Bocca, P., Chiesa, V., Decensi, A., Pistoia, V., Raffaghello, L., Rozzo, C., and Montaldo, P. G. (1995) Cancer Res. 55, 853-861[Abstract]
  11. Elstner, E., Linker-Israeli, M., Umiel, T., Le, J., Grillier, I., Said, J., Shintaku, I. P., Krajewski, S., Reed, J. C., Binderup, L., and Koeffler, H. P. (1996) Cancer Res. 56, 3570-3576[Abstract]
  12. Zhang, X.-k., and Pfahl, M. (1993) TEM 4, 156-162
  13. Kastner, P., Mark, M., and Chambon, P. (1995) Cell 83, 859-869[Medline] [Order article via Infotrieve]
  14. Mangelsdorf, D. J., and Evans, R. M. (1995) Cell 83, 841-850[Medline] [Order article via Infotrieve]
  15. Horwitz, K. B., Jackson, T. A., Bain, D. L., Richer, J. K., Takimoto, G. S., and Tung, L. (1996) Mol. Endocrinol. 10, 1167-1177[Abstract]
  16. Onate, S. A., Tsai, S. Y., Tsai, M.-J., and O'Malley, B. W. (1995) Science 270, 1354-1357[Abstract]
  17. Lee, J. W., Ryan, F., Swaffield, J. C., Johnston, S. A., and Moore, D. D. (1995) Nature 374, 91-94[CrossRef][Medline] [Order article via Infotrieve]
  18. Ledouarin, B., Zechel, C., Garnier, J. M., Lutz, Y., Tora, L., Pierrat, B., Heery, D., Gronemeyer, H., Chambon, P., and Losson, R. (1995) EMBO J. 14, 2020-2033[Abstract]
  19. Cavailles, V., Dauvois, S., Horset, F. L., Lopez, G., Hoare, S., Kushner, P. J., and Parker, M. G. (1995) EMBO J. 14, 3741-3751[Abstract]
  20. Voegel, J. J., Heine, M. J. S., Zechel, C., Chambon, P., and Gronemeyer, H. (1996) EMBO J. 15, 3667-3675[Abstract]
  21. Hong, H., Kohli, K., Trivedi, A., Johnson, D. L., and Stallcup, M. R. G. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 4948-4952[Abstract/Free Full Text]
  22. Halachmi, S., Marden, E., Martin, G., MacKay, H., Abbondanza, C., and Brown, M. (1994) Science 264, 1455-1458[Medline] [Order article via Infotrieve]
  23. Kamei, Y., Xu, L., Heinzel, T., Torchia, J., Kurokawa, R., Gloss, B., Lin, S.-C., Heyman, R. A., Rose, D. W., Glass, C. K., and Rosenfeld, M. G. (1996) Cell 85, 403-414[Medline] [Order article via Infotrieve]
  24. Chen, H., Lin, R. J., Schlitz, R. L., Chakravarti, D., Nash, A., Nagy, Y., Privalsky, M. L., Nakatani, Y., and Evans, R. M. (1997) Cell 90, 569-580[Medline] [Order article via Infotrieve]
  25. Horlein, A. J., Naar, A. M., Heinzel, T., Torchia, J., Gloss, B., Kurokawa, R., Ryan, A., Kamei, Y., Soderstrom, M., Glass, C. K., and Rosenfeld, M. G. (1995) Nature 377, 397-404[CrossRef][Medline] [Order article via Infotrieve]
  26. Chen, J. D., and Evans, R. M. (1995) Nature 377, 454-457[CrossRef][Medline] [Order article via Infotrieve]
  27. Pfahl, M. (1993) Endocr. Rev. 14, 651-658[Medline] [Order article via Infotrieve]
  28. Kochhar, D. M., Jiang, H., Harnish, D. C., and Soprano, D. R. (1993) Prog. Clin. Biol. Res. 383, 815-825
  29. Nagy, L., Thomazy, V. A., Shipley, G. L., Fesus, L., Lamph, W., Heyman, R. A., Chandraratna, R. A., and Davies, P. J. (1995) Mol. Cell Biol. 15, 3540-3551[Abstract]
  30. Fanjul, A. N., Delia, D., Pierotti, M. A., Rideout, D., Qiu, J., and Pfahl, M. (1996) J. Biol. Chem. 271, 22441-22446[Abstract/Free Full Text]
  31. Fanjul, A. N., Bouterfa, H., Dawson, M., and Pfahl, M. (1996) Cancer Res. 56, 1571-1577[Abstract]
  32. Yang, Y., Minucci, S., Ozato, K., Heyman, R. A., and Ashwell, J. D. (1995) J. Biol. Chem. 270, 18672-18677[Abstract/Free Full Text]
  33. Steller, H. (1995) Science 267, 1445-1449[Medline] [Order article via Infotrieve]
  34. Takayama, S., Sato, T., Krajewski, S., Kochel, K., Irie, S., Millan, J. A., and Reed, J. C. (1995) Cell 80, 279-284[Medline] [Order article via Infotrieve]
  35. Packham, G., Brimmell, M., and Cleveland, J. L. (1997) Biochem J. 328, 807-813[Medline] [Order article via Infotrieve]
  36. Clevenger, C. V., Thickman, K., Ngo, W., Chang, W.-P., Takayama, S., and Reed, J. C. (1997) Mol. Endocrinol. 11, 608-618[Abstract/Free Full Text]
  37. Takaoka, A., Adachi, M., Okuda, H., Sato, S., Yawata, A., Hinoda, Y., Takayama, S., Reed, J. C., and Imai, K. (1997) Oncogene 14, 2971-2977[CrossRef][Medline] [Order article via Infotrieve]
  38. Wang, H.-G., Takayama, S., Rapp, U. R., and Reed, J. C. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 7063-7068[Abstract/Free Full Text]
  39. Bardelli, A., Longati, P., Albero, D., Goruppi, S., Schneider, C., Ponzetto, C., and Comoglio, P. M. (1996) EMBO J. 15, 6205-6212[Abstract]
  40. Hohfeld, J., and Jentsch, S. (1997) EMBO J. 16, 6209-6216[Abstract/Free Full Text]
  41. Takayama, S., Bimston, D. N., Matsuzawa, S., Freeman, B. C., Aime-Sempe, C., Xie, Z., Morimoto, R. I., and Reed, J. C. (1997) EMBO J. 16, 4887-4896[Abstract/Free Full Text]
  42. Zeiner, M., Gebauer, M., and Gehring, U. (1997) EMBO J. 16, 5483-5490[Abstract/Free Full Text]
  43. Zeiner, M., and Gehring, U. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 11456-11469[Abstract]
  44. Pratt, W. B., and Toft, D. O. (1997) Endocr. Rev. 18, 306-360[Abstract/Free Full Text]
  45. Zhang, X.-k., Hoffmann, B., Tran, P. B., Graupner, G., and Pfahl, M. (1992) Nature 355, 441-446[CrossRef][Medline] [Order article via Infotrieve]
  46. Hoffmann, B., Lehmann, J. M., Zhang, X.-k., Hermann, T., Graupner, G., and Pfahl, M. (1990) Mol. Endocrinol. 4, 1734-1743
  47. Hermann, T., Hoffmann, B., Zhang, X.-k., Tran, P., and Pfahl, M. (1992) Mol. Endocrinol. 6, 1153-1162[Abstract]
  48. Zhang, X.-k., Lehmann, J., Hoffmann, B., Dawson, M. I., Cameron, J., Graupner, G., Hermann, T., Tran, P., and Pfahl, M. (1992) Nature 358, 587-591[CrossRef][Medline] [Order article via Infotrieve]
  49. Dalman, F. C., Sturzenbecker, L. J., Levin, A. A., Luca, D. A., Perdew, G. H., Petkovitch, M., Chambon, P., Grippo, J. F., and Pratt, W. B. (1991) Biochemistry 30, 5605-5608[Medline] [Order article via Infotrieve]
  50. Holley, S. J., and Yamamoto, K. R. (1995) Mol. Cell. Biol. 6, 1833-1842
  51. Takayama, S., Krajewski, S., Krajewska, M., Kitada, S., Zapata, J., Kochel, K., Knee, D., Miller, G., Scudiero, D., Tudor, G., Sausville, E., and Reed, J. C. (1998) Cancer Res., in press
  52. Wu, Q., Li, Y., Liu, R., Agadir, A., Lee, M.-O., Liu, Y., and Zhang, X.-k. (1997) EMBO J. 16, 1656-1669[Abstract/Free Full Text]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.